SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 9, 2019--
Veracyte,
Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today
announced that Bonnie H. Anderson, chairman and chief executive officer,
is scheduled to present at the UBS Global Healthcare Conference in New
York City on Monday, May 20, 2019 at 9:30 a.m. EDT.
The link to the live audio webcast of the company’s presentation will be
available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations.
A replay of the webcast will be available for 90 days following the
conclusion of the live presentation broadcast.
About Veracyte
Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that
improves patient care by providing trustworthy and actionable answers to
challenging clinical questions. The company's products uniquely combine
advanced genomic technology, clinical science and machine learning to
provide answers that give physicians and patients a clear path forward,
informing both diagnosis and treatment decisions without the need for
costly, risky surgeries that are often unnecessary. Since its founding
in 2008, Veracyte has commercialized five genomic tests which are
transforming the diagnosis of thyroid cancer, lung cancer and idiopathic
pulmonary fibrosis. Veracyte is based in South San Francisco,
California. For more information, please visit www.veracyte.com
and follow the company on Twitter (@veracyte).
View source version on businesswire.com: https://www.businesswire.com/news/home/20190509005849/en/
Source: Veracyte, Inc.
Veracyte Investor & Media Contact:
Angie McCabe
Vice
President, Investor Relations & Corporate Communications
650-243-6371
angie@veracyte.com